Dec 3, 2025 – The Spondylitis Association of America (SAA) has published a new article and featured Augurex’s latest data from the American College of Rheumatology (ACR) 2025 conference in their eSUN newsletter.
Read the full article on the SAA website:
New Research Highlights Promising Advances in AxSpA Diagnosis
The coverage highlights new data on SPINEstat® (Anti-14-3-3eta Multiplex test), a blood-based biomarker assay designed to help clinicians identify axial spondyloarthritis (axSpA) earlier and with greater accuracy. This test also recently received FDA Breakthrough Device Designation, recognizing the significant unmet need in early axSpA diagnosis and the potential for SPINEstat® to improve clinical care.
SAA’s article and newsletter feature summarize findings showing how the Anti-14-3-3eta Multiplex biomarker complements existing tools such as HLA-B27, C-reactive protein, and MRI. Together, these data highlight the value of SPINEstat® in helping clinicians distinguish inflammatory axSpA from mechanical back pain, one of the leading contributors to diagnostic delay.
By sharing these insights with the spondyloarthritis community, SAA continues to advance education and awareness around innovations that support earlier and more confident diagnosis.